Although agents targeting hormone receptors and HER2 can be used to treat hormone receptor-positive and HER2-positive types of breast cancer, these agents are ineffective against TNBC because of the absence of the targeted receptors (ER, PR, and HER2) [7, 8]. The gene discussed is NR4A1; the disease is breast cancer.